Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
AssigneeMerck Sharp & Dohme Corp.
InventorsJennifer H. Yearley, Linda Liang, Michael Eric Bigler, Christopher John Gibson
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
Claims18
An isolated antibody or antigen binding fragment thereof that specifically binds human PD-L2 and comprises three light chain CDRs of CDRL1, CDRL2 and CDRL3 and three heavy chain CDRs of CDRH1, CDRH2 and CDRH3, wherein:
- (a) CDRL1 is the amino acid sequence of SEQ ID NO:2;
- (b) CDRL2 is the amino acid sequence of SEQ ID NO:4;
- (c) CDRL3 is the amino acid sequence of SEQ ID NO:6;
- (d) CDRH1 is the amino acid sequence of SEQ ID NO:10;
- (e) CDRH2 is the amino acid sequence of SEQ ID NO:
- 12;
- and
- (f) CDRH3 is the amino acid sequence of SEQ ID NO:14.
An isolated nucleic acid which encodes one or both of an antibody light chain variable region and an antibody heavy chain variable region, wherein the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:8 and the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:16.
Dependencies are inferred from the claim text.